Triphaus Chris, Judd Leonie, Glaser Patricia, Goehring Marie H, Schmitt Elke, Westphal Sabine, Füllenbach Christoph, Lindau Simone, Zacharowski Kai, Meybohm Patrick, Choorapoikayil Suma
Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main.
Department of Anaesthesiology, University Hospital Wuerzburg, Wuerzburg, Germany.
Ann Surg. 2021 Sep 1;274(3):e212-e219. doi: 10.1097/SLA.0000000000003643.
To evaluate the effectiveness of routine intravenous iron in surgical patients with iron deficiency anemia (IDA).
Anemia is the most common medical disease in the world and is an independent risk factor for morbidity and mortality. Iron deficiency (ID) is the main cause for anemia and constitutes a potentially preventable condition with great impact on surgical outcome.
In this prospective single-center observational study, surgical patients were screened for the presence of anemia and ID. Patients were assigned to 1 of 4 study groups: A- (no anemia); A-, ID+, T+ (no anemia, iron-deficient, iron supplementation); A+ (anemia); and A+, ID+, T+ (anemia, iron-deficient, iron supplementation) according to hemoglobin level, iron status, and supplementation with iron.
Among 1728 patients, 1028 were assigned to A-; 55 to A-, ID+, T+; 461 to A+; and 184 to A+, ID+, T+. While all iron-supplemented IDA patients required less red blood cell (RBC) transfusion during the postoperative period (A+ 42.5% vs A+, ID+, T+ 31.5%), a reduced intraoperative transfusion rate was observed for ID and IDA patients only if iron was supplemented >7 days before surgery. Hospital stay was significantly reduced by 2.8 days in iron-supplemented patients (P < 0.01 comparing 13.9 ± 0.8 days for A+, ID+, T+ vs. 16.7 ± 0.7 days for A+).
Preoperative IDA management with intravenous iron is effective in improving hemoglobin level, thereby reducing intraoperative RBC transfusion rate particular if iron is administrated >7 days before surgery. Hospital length of stay was reduced in all preoperatively iron-supplemented IDA patients.
评估常规静脉补铁对缺铁性贫血(IDA)外科手术患者的有效性。
贫血是全球最常见的内科疾病,是发病和死亡的独立危险因素。缺铁(ID)是贫血的主要原因,是一种对手术结局有重大影响的潜在可预防疾病。
在这项前瞻性单中心观察性研究中,对外科手术患者进行贫血和ID筛查。根据血红蛋白水平、铁状态和铁补充情况,将患者分为4个研究组之一:A-(无贫血);A-,ID+,T+(无贫血,缺铁,补铁);A+(贫血);A+,ID+,T+(贫血,缺铁,补铁)。
在1728例患者中,1028例被分到A-组;55例被分到A-,ID+,T+组;461例被分到A+组;184例被分到A+,ID+,T+组。虽然所有补铁的IDA患者术后所需红细胞(RBC)输注量较少(A+组为42.5%,A+,ID+,T+组为31.5%),但仅当术前7天以上补铁时,ID和IDA患者术中输血率才会降低。补铁患者的住院时间显著缩短2.8天(A+,ID+,T+组为13.9±0.8天,A+组为16.7±0.7天,P<0.01)。
术前用静脉铁剂治疗IDA可有效提高血红蛋白水平,从而降低术中RBC输注率,尤其是术前7天以上补铁时。所有术前补铁的IDA患者住院时间均缩短。